



Fractyl Health, Inc. Securities Fraud Class Action Lawsuit - GUTS

Fractyl Health, Inc.
NASDAQ: GUTS

Affected GUTS Investor Summary

- **Who:** Fractyl Health, Inc. ([NASDAQ: GUTS](#))
 - **What:** Securities fraud class action lawsuit filed
 - **Class Period:** January 13, 2025 through January 29, 2026
 - **Deadline to Seek Lead Plaintiff Status:** October 20, 2026
 - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's lead product candidates efficacy
 - **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](#) for recovery options
-

The *Fractyl Health, Inc.* securities fraud class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Fractyl Health, Inc.* ("*Fractyl*") (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026, inclusive (the "Class Period"). Captioned *Lorne v. Fractyl Health, Inc.*, No. 26-cv-07167 (S.D.N.Y.), the *Fractyl* class action lawsuit alleges that *Fractyl* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Fractyl* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than October 20, 2026.

COMPLAINT ALLEGATION SUMMARY:

Fractyl is a metabolic therapeutics company that develops therapies for the treatment of type 2 diabetes and obesity. One of the company's products in development is the Revita DMR System ("*Revita*"), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) *Revita* was less effective than it was held out to be; (2) operational issues at one or more of the relevant clinical sites compromised the integrity of *Revita*'s efficacy results; (3) *Revita*'s clinical, regulatory, and commercial prospects were overstated; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID FRACTYL'S STOCK DROP?

On January 29, 2026, *Fractyl* issued a press release that disclosed, in part, that Revita showed lower efficacy results than previously disclosed. That same day, *Fractyl* indicated that the issues at one of the study sites were at least partially to blame for the disappointing results. On this news, *Fractyl's* stock price fell more than 68%.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Fractyl* securities during the Class Period to seek appointment as lead plaintiff in the *Fractyl* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being [recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm](#) in Securities and Class Actions, [Legal 500's Tier 1 Rankings for Securities and M&A Litigation](#), The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's [Class Action Firm of the Year](#), Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

